Distribution of ceftazidime in ascitic fluid
- PMID: 6378086
- PMCID: PMC185636
- DOI: 10.1128/AAC.25.6.760
Distribution of ceftazidime in ascitic fluid
Abstract
The pharmacokinetics of ceftazidime were investigated in eight normal subjects and eight patients with ascites after intravenous administration of 1 g of the drug. Samples of blood and ascitic fluid were collected for 6 h after dosage, and urine samples were collected for 24 h. Pharmacokinetic data were calculated by using a one-compartment model. The apparent volume of distribution and half-life of elimination (t1/2 beta) in patients with ascites were approximately three times those in normal subjects. In contrast, renal clearance was greater in the normal subjects. With respect to ascites, the mean area under the concentration-time curve was 95.3 +/- 38.3 micrograms X h/ml. The mean ratio of the area under the concentration-time curve for ascitic fluid to that for plasma was 69.9% (+/- 38.2). These data show that ceftazidime rapidly diffuses into the peritoneal space, in which concentrations greater than 10 micrograms/ml were present for at least 6 h.
Similar articles
-
Pharmacokinetics of ceftazidime in sheep and its penetration into tissue and peritoneal fluids.Res Vet Sci. 1991 Nov;51(3):233-8. doi: 10.1016/0034-5288(91)90069-z. Res Vet Sci. 1991. PMID: 1780573
-
Pharmacokinetics of ceftazidime in normal and uremic subjects.Antimicrob Agents Chemother. 1984 May;25(5):638-42. doi: 10.1128/AAC.25.5.638. Antimicrob Agents Chemother. 1984. PMID: 6375562 Free PMC article.
-
The kinetics of cefuroxime in ascitic and pleural fluid.Int J Clin Pharmacol Ther Toxicol. 1982 Oct;20(10):493-6. Int J Clin Pharmacol Ther Toxicol. 1982. PMID: 6815108
-
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Drugs. 2019. PMID: 30712199 Review.
-
Cefpirome clinical pharmacokinetics.Clin Pharmacokinet. 1993 Oct;25(4):263-73. doi: 10.2165/00003088-199325040-00002. Clin Pharmacokinet. 1993. PMID: 8261711 Review.
Cited by
-
Dosage adjustment for ceftazidime in patients with impaired renal function.Eur J Clin Pharmacol. 1986;30(5):597-605. doi: 10.1007/BF00542421. Eur J Clin Pharmacol. 1986. PMID: 3530782
-
Clinical pharmacokinetics of the third generation cephalosporins.Clin Pharmacokinet. 1985 Mar-Apr;10(2):101-43. doi: 10.2165/00003088-198510020-00001. Clin Pharmacokinet. 1985. PMID: 3888488 Review.
-
Clinical pharmacokinetics of newer antibacterial agents in liver disease.Clin Pharmacokinet. 1993 Jan;24(1):46-58. doi: 10.2165/00003088-199324010-00004. Clin Pharmacokinet. 1993. PMID: 8448972 Review.
-
Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration.Antimicrob Agents Chemother. 1993 Mar;37(3):464-73. doi: 10.1128/AAC.37.3.464. Antimicrob Agents Chemother. 1993. PMID: 8460915 Free PMC article.
-
Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.Drugs. 1985 Feb;29(2):105-61. doi: 10.2165/00003495-198529020-00002. Drugs. 1985. PMID: 3884319 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources